Exact Sciences (EXAS) shares tumbled 5.35% in pre-market trading on Thursday amid multiple price target cuts from Wall Street analysts.
Barclays analyst Luke Sergott lowered the firm's price target on EXAS to $65 from $70, while maintaining an Overweight rating on the stock. BTIG also cut its price target on the molecular diagnostics company to $65 from $75, but kept a Buy rating following Exact Sciences' Q4 results and guidance.
Additionally, Jefferies trimmed its price target on EXAS to $80 from $85 as part of its broader research roundup on U.S. companies.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。